Cargando…

Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care

INTRODUCTION: This research was to follow characteristics of breakthrough pain caused by cancer (BTcP) and other most common sympthoms (ESAS) at patients in advanced stage of cancer disease in palliative care. PATIENTS AND METHODS: Prospective study included 433 patients which were treated in Pallia...

Descripción completa

Detalles Bibliográficos
Autores principales: Husic, Samir, Imamovic, Semir, Matic, Srecko, Sukalo, Aziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AVICENA, d.o.o., Sarajevo 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585809/
https://www.ncbi.nlm.nih.gov/pubmed/28974843
http://dx.doi.org/10.5455/medarh.2017.71.246-250
_version_ 1783261698647392256
author Husic, Samir
Imamovic, Semir
Matic, Srecko
Sukalo, Aziz
author_facet Husic, Samir
Imamovic, Semir
Matic, Srecko
Sukalo, Aziz
author_sort Husic, Samir
collection PubMed
description INTRODUCTION: This research was to follow characteristics of breakthrough pain caused by cancer (BTcP) and other most common sympthoms (ESAS) at patients in advanced stage of cancer disease in palliative care. PATIENTS AND METHODS: Prospective study included 433 patients which were treated in Palliative Care Centre in UKC Tuzla, Bosnia and Herzegovina. Group 1 was consisted of 353 patients whose basal cancer pain of intensity 4-7 NRS was treated weak opiates (basal analgetic- fixed combination of tramadol/paracetamol (37.5 mg/325 mg) in initial dose 3x1tbl for pain intensity 4, to 4x2tbl (for pain intensity 7). In Group 2 (80 patients) basal pain of intensity 8-10 was treated strong opiates as basal analgetic (oral morphine and transdermal fentanil). If the previous day were 2 or more breakthrough pain that required ‘’rescue dose’’ of analgetics (tramadol 50-100 mg orally in group 1 ie. Oral morphine 8-12 mg in the group 2), the dose of basal analgetic was increased. RESULTS: The total number of reported breakthrough pain in all 433 patients for 10 days of treatment was 3 369 (0.78 BTcP /per patient/day), where at Group 1 patients showed significantly lower BTcP (0.56 BTcP/patient/day). The average intensity of BTcP was 5.91 where in the Group1 was 4.51 while in the Group 2 8.04. 582 (17.28%) was rated grade 7, of which 539 were successfully coupled by strong and 43 (7.39%) successfully coupled by weak opiates. From 556 BTcP who were rated with 8, 540 of them were coupled strong and only 16 successfully coupled by weak opiates. 1967 (58.39 %) of breakthrough pain has occured in the evening hours (18-06 h), while 1402 (41.62%) BTCP occured during day hours (06-18h). Most (1290 or 38.29%) of breakthrough pain lasted less than 10 minutes, 882 (26.18%) between 16 and 20 minutes, 752 (22.32%) between 11 and 15 minutes, 407 (12.8%) between 21 and 30 minutes and 38 (1.13%) lasted longer than 20 minutes. CONCLUSION: Duriong our study, we noted a relatively large number of breakthrough pain with lower intensity (3-6) in patients treated with weak opiates, which are also adversely affected patients satisfaction with pain treatment and required additional doses of analgetics. In the small percentage is possible the breakthrough pain of stronger intensity (7-8) treat by maximum doses of weak opiates.
format Online
Article
Text
id pubmed-5585809
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AVICENA, d.o.o., Sarajevo
record_format MEDLINE/PubMed
spelling pubmed-55858092017-10-03 Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care Husic, Samir Imamovic, Semir Matic, Srecko Sukalo, Aziz Med Arch Original Paper INTRODUCTION: This research was to follow characteristics of breakthrough pain caused by cancer (BTcP) and other most common sympthoms (ESAS) at patients in advanced stage of cancer disease in palliative care. PATIENTS AND METHODS: Prospective study included 433 patients which were treated in Palliative Care Centre in UKC Tuzla, Bosnia and Herzegovina. Group 1 was consisted of 353 patients whose basal cancer pain of intensity 4-7 NRS was treated weak opiates (basal analgetic- fixed combination of tramadol/paracetamol (37.5 mg/325 mg) in initial dose 3x1tbl for pain intensity 4, to 4x2tbl (for pain intensity 7). In Group 2 (80 patients) basal pain of intensity 8-10 was treated strong opiates as basal analgetic (oral morphine and transdermal fentanil). If the previous day were 2 or more breakthrough pain that required ‘’rescue dose’’ of analgetics (tramadol 50-100 mg orally in group 1 ie. Oral morphine 8-12 mg in the group 2), the dose of basal analgetic was increased. RESULTS: The total number of reported breakthrough pain in all 433 patients for 10 days of treatment was 3 369 (0.78 BTcP /per patient/day), where at Group 1 patients showed significantly lower BTcP (0.56 BTcP/patient/day). The average intensity of BTcP was 5.91 where in the Group1 was 4.51 while in the Group 2 8.04. 582 (17.28%) was rated grade 7, of which 539 were successfully coupled by strong and 43 (7.39%) successfully coupled by weak opiates. From 556 BTcP who were rated with 8, 540 of them were coupled strong and only 16 successfully coupled by weak opiates. 1967 (58.39 %) of breakthrough pain has occured in the evening hours (18-06 h), while 1402 (41.62%) BTCP occured during day hours (06-18h). Most (1290 or 38.29%) of breakthrough pain lasted less than 10 minutes, 882 (26.18%) between 16 and 20 minutes, 752 (22.32%) between 11 and 15 minutes, 407 (12.8%) between 21 and 30 minutes and 38 (1.13%) lasted longer than 20 minutes. CONCLUSION: Duriong our study, we noted a relatively large number of breakthrough pain with lower intensity (3-6) in patients treated with weak opiates, which are also adversely affected patients satisfaction with pain treatment and required additional doses of analgetics. In the small percentage is possible the breakthrough pain of stronger intensity (7-8) treat by maximum doses of weak opiates. AVICENA, d.o.o., Sarajevo 2017-08 /pmc/articles/PMC5585809/ /pubmed/28974843 http://dx.doi.org/10.5455/medarh.2017.71.246-250 Text en Copyright: © 2017 Samir Husic, Semir Imamovic, Srecko Matic, Aziz Sukalo http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Husic, Samir
Imamovic, Semir
Matic, Srecko
Sukalo, Aziz
Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care
title Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care
title_full Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care
title_fullStr Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care
title_full_unstemmed Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care
title_short Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care
title_sort characteristics and treatment of breakthrought pain (btcp) in palliative care
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585809/
https://www.ncbi.nlm.nih.gov/pubmed/28974843
http://dx.doi.org/10.5455/medarh.2017.71.246-250
work_keys_str_mv AT husicsamir characteristicsandtreatmentofbreakthroughtpainbtcpinpalliativecare
AT imamovicsemir characteristicsandtreatmentofbreakthroughtpainbtcpinpalliativecare
AT maticsrecko characteristicsandtreatmentofbreakthroughtpainbtcpinpalliativecare
AT sukaloaziz characteristicsandtreatmentofbreakthroughtpainbtcpinpalliativecare